ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。

AIM AIM ImmunoTech Inc

0.429
0.0205 (5.02%)
プレマーケット
最終更新日: 21:32:31
15分遅延
名称 銘柄コード 市場 種別
AIM ImmunoTech Inc AIM AMEX 普通株式
  前日比 前日比 % 現在値 時刻
0.0205 5.02% 0.429 21:32:31
始値 安値 高値 終値 前日終値
0.4085
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/2921:55GLOBEAIM ImmunoTech Announces First Dose Level is Generally..
2024/4/2521:45GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
2024/4/1821:45GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
2024/4/1521:55GLOBEAIM ImmunoTech Announces Charles Lapp, MD, as a Consulting..
2024/4/1200:00GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
2024/4/1021:21GLOBEAIM ImmunoTech Announces Positive Top-Line, Protocol-Planned..
2024/4/0220:30GLOBEAIM ImmunoTech Reports Fourth Quarter and Full Year 2023..
2024/3/2821:05GLOBEAIM ImmunoTech to Present at the MedInvest Biotech & Pharma..
2024/3/2622:05GLOBEAIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023..
2024/3/2522:05GLOBEAIM ImmunoTech Announces Publication of Positive Findings..
2024/3/2221:55GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
2024/3/2022:25GLOBEAIM ImmunoTech Announces Release of the Next CEO Corner..
2024/3/1521:45GLOBEAIM ImmunoTech to Participate in the Virtual Investor Lunch..
2024/3/0722:45GLOBEAIM ImmunoTech Announces Launch of CEO Corner Platform
2024/2/2922:45GLOBEAIM ImmunoTech Outlines Recent Progress Across Clinical..
2024/2/2200:37EDGAR2Form D/A - Notice of Exempt Offering of Securities: [Amend]
2024/2/2106:31EDGAR2Form 8-K - Current report
2024/2/1422:55GLOBEAIM ImmunoTech Announces First Subject Dosed in the..
2024/2/1005:47EDGAR2Form 8-K - Current report
2024/2/0822:50GLOBEAIM ImmunoTech Reports Positive Topline Results from Phase 2..
2024/1/2607:00EDGAR2Form 8-K - Current report
2024/1/2423:10GLOBEAIM ImmunoTech Receives Erasmus Medical Center Ethics Board..
2024/1/2222:55GLOBEAIM ImmunoTech Announces that the First Subject is Enrolled..
2024/1/1103:42EDGAR2Form 8-K - Current report
2024/1/1022:45EDGAR2Form 8-K - Current report
2024/1/1022:45GLOBEAIM ImmunoTech Announces Open Enrollment for Phase 1b/2..
2024/1/0603:32BWAIM Shareholders Elect All Four Company Director Nominees at..
2024/1/0406:24EDGAR2Form SC 13D/A - General statement of acquisition of..
2024/1/0406:24EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
2024/1/0406:05PRNUSKellner Seeking Expedited Appeal of Delaware Court Finding..
2023/12/2922:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/12/2922:00BWDelaware Court Rules in Favor of AIM ImmunoTech and Upholds..
2023/11/2906:54EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/11/2906:30BWAIM ImmunoTech Provides Update Regarding Annual Meeting
2023/11/2802:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/11/2723:05GLOBEAIM ImmunoTech Bolsters Intellectual Property Estate for..
2023/11/2202:00GLOBEAIM ImmunoTech Completes Treatment of Last Subject in Phase..
2023/11/2107:29EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/11/2023:05EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
2023/11/2021:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/11/1623:21EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
2023/11/1521:30EDGAR2Form 8-K - Current report
2023/11/1521:30GLOBEAIM ImmunoTech Reports Third Quarter 2023 Financial Results..
2023/11/1500:00GLOBEAIM ImmunoTech Announces Publication of Data from Roswell..
2023/11/0922:05GLOBEAIM ImmunoTech to Discuss Third Quarter 2023 Financial..
2023/11/0906:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/11/0822:45EDGAR2Form 8-K - Current report
2023/11/0822:45GLOBEAIM ImmunoTech Announces Encouraging Translational Data from..
2023/11/0720:03EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/11/0623:25BWAIM ImmunoTech Files Definitive Proxy Statement and Sends..

最近閲覧した銘柄

Delayed Upgrade Clock